https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-01 / Curr. Opin. Mol. Ther. 2008 Aug;10(4):371-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-01 / Curr. Opin. Mol. Ther. 2008 Aug;10(4):371-92008-08-01 00:00:002019-02-15 09:21:59Virus combinations and chemotherapy for the treatment of human cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-01 / Int. J. Cancer 2008 Aug;123(3):493-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-01 / Int. J. Cancer 2008 Aug;123(3):493-92008-08-01 00:00:002019-02-15 09:22:02Oncolytic virotherapy as a personalized cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-06 / Cancer Gene Ther. 2008 Dec;15(12):795-8072008-06-06 00:00:002008-06-06 00:00:00Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-802008-06-05 00:00:002021-11-15 17:04:06Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-92008-05-17 00:00:002021-11-15 17:04:52Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-892008-04-01 00:00:002021-11-15 17:05:15An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-03-04 / J. Neuroimmunol. 2008 Mar;195(1-2):21-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-03-04 / J. Neuroimmunol. 2008 Mar;195(1-2):21-72008-03-04 00:00:002019-02-15 09:22:04Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-15 / Biochim. Biophys. Acta 2008 Apr;1785(2):217-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-15 / Biochim. Biophys. Acta 2008 Apr;1785(2):217-312008-02-15 00:00:002019-02-15 09:22:03Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-72008-02-13 00:00:002021-11-15 17:05:45Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-17 / Gene Ther. 2008 Mar;15(5):371-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-17 / Gene Ther. 2008 Mar;15(5):371-832008-01-17 00:00:002019-02-15 09:22:05Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes
